Glenmark Pharmaceuticals Nordic AB: vundne offentlige udbud

Ifølge tildelingsbekendtgørelser i TED har Glenmark Pharmaceuticals Nordic AB vundet 9 udbud hos danske ordregivere med en samlet oplyst værdi på 1.672.018.074 kr.. Den seneste tildeling er dateret 25. oktober 2026.

UdbudOrdregiverVindereVærdiDato
Amgros 2027 1.604.aAmgros I/SViatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S284.601.687 kr.25. oktober 2026
Amgros 2027 1.604.aAmgros I/SViatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S284.601.687 kr.25. oktober 2026
Amgros 2027 1.604.aAmgros I/SViatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S284.601.687 kr.25. oktober 2026
Amgros 2027 1.604.aAmgros I/SViatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S284.601.687 kr.25. oktober 2026
Amgros 2027 1.604.aAmgros I/SViatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S284.601.687 kr.25. oktober 2026
Amgros 2027 2.212.aAmgros I/SOrion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB33.641.330 kr.13. oktober 2026
Amgros 2027 2.212.aAmgros I/SOrion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB33.641.330 kr.13. oktober 2026
Amgros 2027 2.212.aAmgros I/SOrion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB33.641.330 kr.13. oktober 2026
Amgros 2027 1.1203.aAmgros I/SNavamedic AB, Hameln Pharma ApS, Macure Pharma ApS, Hameln Pharma ApS, Orifarm A/S, 2care4 ApS, Viatris ApS, Glenmark Pharmaceuticals Nordic AB, Øresund Pharma ApS, Sandoz A/S, Orifarm A/S, Paranova Danmark A/S, Vingmed A/S, Abacus Medicine A/S, Paranova Danmark A/S148.085.649 kr.13. oktober 2026

Datakilde: TED © Den Europæiske Union. Tildelingsbekendtgørelser fra danske ordregivere.

Vinderbadge til din hjemmeside

Repræsenterer du Glenmark Pharmaceuticals Nordic AB? Kopiér koden og indsæt den på jeres hjemmeside. Badget linker til denne side.

Forhåndsvisning:

🏆 Glenmark Pharmaceuticals Nordic AB har vundet offentlige udbud – se udbuddene på EU-udbud.dk